Boston Scientific Stock Dips On Dull Preliminary Q4 Results
Zacks Investment Research | Jan 14, 2020 10:18PM ET
Boston Scientific Corporation (NYSE:BSX) announced preliminary revenue results for the fourth quarter and 2019. The company is slated to release its detailed financial results for the period on Feb 4.
Per the announcement, Boston Scientific’s organic revenue growth rates for both fourth-quarter and 2019 are expected to be below the earlier provided figures. This fails to instill investors’ confidence, which is reflected through a 6.2% dip in stock price that reached $42.66 on Jan 14 at the closing.
For the to-be-reported quarter, Boston Scientific expects total revenue growth of 13.4% to $2.90 billion from the year-ago reported figure, indicating 14.1% rise on an operational basis and 7.3% improvement on an organic basis. Notably, the company’s expectation for the same is below the Zacks Consensus Estimate of $2.92 billion. The preliminary figures are near the low end of the company’s guidance of 13-15% (reported basis), 14-16% (operational basis) and 8-9% (organically).
Per Boston Scientific, revenues in the fourth quarter improved in all segments, except for Specialty Pharmaceuticals. Data for the Specialty Pharmaceuticals is unavailable due to its integration, since the BTG acquisition in August 2019. Excluding acquisitions and divestitures, the company's total revenues are predicted to increase 6.8%.
For the year, Boston Scientific expects a 9.3% year-over-year improvement in total revenues to $10.74 billion, suggesting 11.1% rise on an operational basis and a 7.3% increase on an organic basis. Notably, the company’s expectation for the same is marginally above the Zacks Consensus Estimate of $10.73 billion. For 2019, revenues in all the reported segments were strong, except for Specialty Pharmaceuticals.
Segmental Expectations
For the fourth quarter, MedSurg (30.8% of total revenues) is likely to rise 9.8% on a reported basis, and 10.6% on both operational (excluding currency fluctuation) and organic basis.
Rhythm and Neuro (29.2% of total revenues) is likely to rise 3.5% on a reported basis, 4.1% on an operational basis and 1% on an organic basis.
Cardiovascular (39.2% of total revenues) is likely to rise 18.7% on a reported basis, 19.3% on an operational basis and 10% on an organic basis.
Get The News You Want
Per the company’s updated outlook, earnings per share (EPS) on a reported basis are likely to exceed 22-25 cents mentioned earlier for the fourth quarter and 72-75 cents stated previously for the year.
The adjusted EPS, excluding certain charges (credits), is likely to be within the company’s guidance of 42-45 cents and $1.55-1.58 for the fourth quarter and 2019, respectively.
Price Performance
Shares of Boston Scientific have gained 16.5% in the past year compared with the Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.